Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) said it and its collaboration partners will be presenting information related to its phase II clinical trial.
One poster at an industry conference this week will include validation data of muscle biopsy biomarkers used to assess utrophin modulator activity.
Utrophin control is central to Summit drug ezutromid, which is a potential treatment for boys with the incurable muscle wasting disease, Duchenne Muscular Dystrophy (DMD).
The biomarker breakthrough has come out of Summit’s collaboration with Flagship Biosciences.
"Developing new biomarkers capable of more reliably analysing muscle biopsies in clinical trials has been a major priority for Summit, and I am delighted with the progress made in our collaboration with Flagship,” said Dr David Roblin, the company’s chief medical officer.
“These automated techniques are capable of analysing thousands of muscle fibres in whole muscle biopsy sections, and we believe that their use could help us establish proof of mechanism for our utrophin modulator, ezutromid, in our ongoing PhaseOut DMD clinical trial."
The AIM and NASDAQ-listed life sciences company will also share baseline characteristics of patients enrolled into Summit's ongoing PhaseOut DMD study.
The conference, the 22nd International Congress of the World Muscle Society, is currently taking place in Saint-Malo, France.